Your browser doesn't support javascript.
loading
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink, Antoinette; Terwindt, Gisela M; Cohen, Joshua M; Barash, Steve; Campos, Verena Ramirez; Galic, Maja; Ning, Xiaoping; Kärppä, Mikko.
Affiliation
  • MaassenVanDenBrink A; Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands. a.vanharen-maassenvandenbrink@erasmusmc.nl.
  • Terwindt GM; Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Cohen JM; Teva Pharmaceutical Products R&D, Inc., PA, West Chester, USA.
  • Barash S; Teva Pharmaceutical Products R&D, Inc., PA, West Chester, USA.
  • Campos VR; Teva Pharmaceutical Products R&D, Inc., PA, West Chester, USA.
  • Galic M; Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands.
  • Ning X; Teva Pharmaceutical Products R&D, Inc., PA, West Chester, USA.
  • Kärppä M; Research Unit of Clinical Neuroscience, University of Oulu and Medical Research Center, Oulu University Hospital, Oulu, Finland.
J Headache Pain ; 22(1): 152, 2021 Dec 18.
Article in En | MEDLINE | ID: mdl-34922436
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Migraine Disorders / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Migraine Disorders / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Year: 2021 Type: Article